Surgical resection after gefitinib treatment in patients with lung adenocarcinoma harboring epidermal growth factor receptor gene mutation

Lung Cancer

Volumn 58, Issue 1, 2007, Pages 149-155

  Takamochi, Kazuya ^a   Suzuki, Kazuya ^a   Sugimura, Haruhiko ^a   Funai, Kazuhito ^a   Mori, Hiroki ^a   Bashar, Abul Hasan Muhammad ^a   Kazui, Teruhisa ^a  

^a HAMAMATSU UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

Epidermal growth factor receptor; Gefitinib; Induction therapy; Lung cancer; Mutation; Salvage surgery

Indexed keywords

CARBOPLATIN; CARCINOEMBRYONIC ANTIGEN; EPIDERMAL GROWTH FACTOR RECEPTOR; GEFITINIB; PACLITAXEL; SQUAMOUS CELL CARCINOMA ANTIGEN;

ADULT; AGED; ARTICLE; CANCER DIAGNOSIS; CANCER STAGING; CANCER SURGERY; CASE REPORT; COMPUTER ASSISTED TOMOGRAPHY; FEMALE; GENE DELETION; GENE MUTATION; GENETIC ANALYSIS; HUMAN; HUMAN TISSUE; LIVER TOXICITY; LUNG ADENOCARCINOMA; LUNG LOBECTOMY; LUNG METASTASIS; MINIMAL RESIDUAL DISEASE; MULTIPLE CYCLE TREATMENT; PRIORITY JOURNAL; SURGICAL TECHNIQUE; TRANSBRONCHIAL BIOPSY; TREATMENT DURATION; TREATMENT OUTCOME; TREATMENT RESPONSE;

ADENOCARCINOMA; AGED; ANTINEOPLASTIC AGENTS; FEMALE; GENES, ERBB-1; HUMANS; LUNG NEOPLASMS; MIDDLE AGED; MUTATION; NEOPLASM, RESIDUAL; PROTEIN KINASE INHIBITORS; QUINAZOLINES; RECEPTOR, EPIDERMAL GROWTH FACTOR;

EID: 34548515333     PISSN: 01695002     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.lungcan.2007.04.016     Document Type: Article

References (20)

1. Fukuoka M., Yano S., Giaccone G., Tamura T., Nakagawa K., Douillard J.Y., et al. Multi-institutional randomized phase II trial of gefitinib for previously treated patients with advanced non-small cell lung cancer (The IDEAL 1 Trial) [corrected]. J Clin Oncol 21 (2003) 2237-2246
2. Kris M.G., Natale R.B., Herbst R.S., Lynch Jr. T.J., Prager D., Belani C.P., et al. Efficacy of gefitinib, an inhibitor of the epidermal growth factor receptor tyrosine kinase, in symptomatic patients with non-small cell lung cancer: a randomized trial. JAMA 290 (2003) 2149-2158
3. Han S.W., Kim T.Y., Hwang P.G., Jeong S., Kim J., Choi I.S., et al. Predictive and prognostic impact of epidermal growth factor receptor mutation in non-small cell lung cancer patients treated with gefitinib. J Clin Oncol 23 (2005) 2493-2501
4. Mitsudomi T., Kosaka T., Endoh H., Horio Y., Hida T., Mori S., et al. Mutations of the epidermal growth factor receptor gene predict prolonged survival after gefitinib treatment in patients with non-small cell lung cancer with postoperative recurrence. J Clin Oncol 23 (2005) 2513-2520
5. Cappuzzo F., Hirsch F.R., Rossi E., Bartolini S., Ceresoli G.L., Bemis L., et al. Epidermal growth factor receptor gene and protein and gefitinib sensitivity in non-small cell lung cancer. J Natl Cancer Inst 97 (2005) 643-655
6. Hirsch F.R., Varella-Garcia M., McCoy J., West H., Xavier A.C., Gumerlock P., et al. Increased epidermal growth factor receptor gene copy number detected by fluorescence in situ hybridization associates with increased sensitivity to gefitinib in patients with bronchioloalveolar carcinoma subtypes: a Southwest Oncology Group Study. J Clin Oncol 23 (2005) 6838-6845
7. Thatcher N., Chang A., Parikh P., Rodrigues Pereira J., Ciuleanu T., von Pawel J., et al. Gefitinib plus best supportive care in previously treated patients with refractory advanced non-small cell lung cancer: results from a randomised, placebo-controlled, multicentre study (Iressa Survival Evaluation in Lung Cancer). Lancet 366 (2005) 1527-1537
8. Nagai Y., Miyazawa H., Huqun, Tanaka T., Udagawa K., Kato M., et al. Genetic heterogeneity of the epidermal growth factor receptor in non-small cell lung cancer cell lines revealed by a rapid and sensitive detection system, the peptide nucleic acid-locked nucleic acid PCR clamp. Cancer Res 65 (2005) 7276-7282
9. Martini N., and Melamed M.R. Multiple primary lung cancers. J Thorac Cardiovasc Surg 70 (1975) 606-612
10. Inoue A., Suzuki T., Fukuhara T., Maemondo M., Kimura Y., Morikawa N., et al. Prospective phase II study of gefitinib for chemotherapy-naive patients with advanced non-small cell lung cancer with epidermal growth factor receptor gene mutations. J Clin Oncol 24 (2006) 3340-3346
11. Asahina H., Yamazaki K., Kinoshita I., Sukoh N., Harada M., Yokouchi H., et al. A phase II trial of gefitinib as first-line therapy for advanced non-small cell lung cancer with epidermal growth factor receptor mutations. Br J Cancer 95 (2006) 998-1004
12. Sutani A., Nagai Y., Udagawa K., Uchida Y., Koyama N., Murayama Y., et al. Gefitinib for non-small cell lung cancer patients with epidermal growth factor receptor gene mutations screened by peptide nucleic acid-locked nucleic acid PCR clamp. Br J Cancer 95 (2006) 1483-1489
13. Kobayashi S., Boggon T.J., Dayaram T., Janne P.A., Kocher O., Meyerson M., et al. EGFR mutation and resistance of non-small cell lung cancer to gefitinib. N Engl J Med 352 (2005) 786-792
14. Pao W., Miller V.A., Politi K.A., Riely G.J., Somwar R., Zakowski M.F., et al. Acquired resistance of lung adenocarcinomas to gefitinib or erlotinib is associated with a second mutation in the EGFR kinase domain. PLoS Med 2 (2005) e73
15. Kosaka T., Yatabe Y., Endoh H., Yoshida K., Hida T., Tsuboi M., et al. Analysis of epidermal growth factor receptor gene mutation in patients with non-small cell lung cancer and acquired resistance to gefitinib. Clin Cancer Res 12 (2006) 5764-5769
16. Nakagawa K., Tamura T., Negoro S., Kudoh S., Yamamoto N., Takeda K., et al. Phase I pharmacokinetic trial of the selective oral epidermal growth factor receptor tyrosine kinase inhibitor gefitinib ('Iressa', ZD1839) in Japanese patients with solid malignant tumors. Ann Oncol 14 (2003) 922-930
17. Ranson M., Hammond L.A., Ferry D., Kris M., Tullo A., Murray P.I., et al. ZD1839, a selective oral epidermal growth factor receptor-tyrosine kinase inhibitor, is well tolerated and active in patients with solid, malignant tumors: results of a phase I trial. J Clin Oncol 20 (2002) 2240-2250
18. Herbst R.S., Maddox A.M., Rothenberg M.L., Small E.J., Rubin E.H., Baselga J., et al. Selective oral epidermal growth factor receptor tyrosine kinase inhibitor ZD1839 is generally well-tolerated and has activity in non-small cell lung cancer and other solid tumors: results of a phase I trial. J Clin Oncol 20 (2002) 3815-3825
19. Baselga J., Rischin D., Ranson M., Calvert H., Raymond E., Kieback D.G., et al. Phase I safety, pharmacokinetic, and pharmacodynamic trial of ZD1839, a selective oral epidermal growth factor receptor tyrosine kinase inhibitor, in patients with five selected solid tumor types. J Clin Oncol 20 (2002) 4292-4302
20. Govindan R., Behnken D., Read W., and McLeod H. Wound healing is not impaired by the epidermal growth factor receptor-tyrosine kinase inhibitor gefitinib. Ann Oncol 14 (2003) 1330-1331